COMMENTS TO THE PAPER «RAMIPRIL SENSITAZES PLATELETS TO NITRIC OXIDE. IMPLICATION FOR THERAPY IN HIGH-RISK PATIENTS»

1. National guidelines for diagnosis and treatment of hypertension (4th revision). Sistemye Gipertenzii 2010; (3): 5–26. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертонии (четвертый пересмотр) Системные гипертензии 2010; (3): 5–26).

2. National guidelines for diagnosis and treatment of chronic heart failure (second revision). Serdechnaya nedostatochnost' 2006; 8(2): 1–35. Russian (Национальные рекомендации по диагностике и лечению хронической сердечной недостаточности (второй пересмотр). Сердечная недостаточность 2006; 8(2): 1–35).

3. НOPE study investigators. Effects of an angiotensin-converting-enzyme inhibitor , ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53.

4. The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362; 782–788.

5. Bonner G, Preis S, Schunck U et al. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol 1990; 15 (suppl 6): 46–56.

6. Busse R, Lamontagne D. Endothelium–derived bradykinin is responsible for the increase in calcium produced by angiotensin–converting enzyme inhibitors in human endothelial cells. Naunyn–Schmiede-bergs Arch Pharmacol 1991; 344:126–9.

7. Lonn E.M., Yusuf S., Dzavic V . et al. Effects of ramipril and vitamin E on atherosclerosis: treated with ramipril and vitamin E (SECURE). Circulation 2001:103:919–25.

8. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25(6):1105–87.

9. Chirkov Y .Y ., Holmes A.S., Willoughby S.R., et al. Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets. J Am Coll Cardiol 2001;37:1851–7.

10. Anfossi G., Russo I., Massucco P ., et al. Platelet resistance to the antiaggregating effect of N-acetyl-L-cysteine in obese, insulin-resistant subjects. Thromb Res 2003; 110: 39–46.

11. Willoughby S.R., Rajendran S., Chan W.P . Ramipril Sensitizes Platelets to Nitric Oxide: Implications for Therapy in High-Risk Patients. J Am Coll Cardiol 2012 May 23 [Epub ahead of print].